Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
2. 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2z)-but-2-enedioate
3. 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2z)-but-2-enedioate (1:1)
4. Azd 2171
5. Azd-2171
6. Azd-2171 Maleate
7. Azd2171
8. Azd2171 Maleate
9. Cediranib Maleate
10. Recentin
1. 288383-20-0
2. Recentin
3. Azd2171
4. Cedirannib
5. Cediranib (azd2171)
6. Azd 2171
7. Azd-2171
8. 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
9. Cediranib Free Base
10. 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
11. Cediranib (azd217)
12. Azd-2171 Maleate
13. 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
14. Nqu9ipy4k9
15. Zd-2171
16. 4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
17. Chembl491473
18. 288383-20-0 (free Base)
19. Nsc-732208
20. 4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
21. Cediranib [inn]
22. Quinazoline, 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)propoxy)-
23. Kinome_3318
24. Cediranib (usan/inn)
25. Unii-nqu9ipy4k9
26. Cediranib [usan:inn:ban]
27. 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
28. 4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
29. Cediranib,azd2171
30. Cediranib Dihydrochloride
31. Azd2171, Cediranib
32. Cediranib [usan]
33. Cediranib - Azd2171
34. Cediranib [mart.]
35. Cediranib [who-dd]
36. Schembl63147
37. Mls006010063
38. Gtpl5664
39. Chebi:94782
40. Dtxsid10183035
41. Bcpp000295
42. Hms3654g05
43. Hms3674g17
44. Hms3744o21
45. Amy16021
46. Bcp01378
47. Ex-a2039
48. Zinc3948085
49. Bdbm50331096
50. Mfcd09954115
51. Nsc755606
52. Nsc800069
53. S1017
54. Akos005145767
55. Bcp9000500
56. Ccg-264679
57. Cs-0119
58. Db04849
59. Es-0052
60. Nsc-755606
61. Nsc-800069
62. Sb16536
63. Zd 2171
64. Ncgc00263097-01
65. Ncgc00263097-09
66. Ac-25033
67. Hy-10205
68. Quinazoline,4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-
69. Smr004701223
70. Ft-0751000
71. Sw219261-1
72. Ec-000.2328
73. A24280
74. D08881
75. Q-101399
76. Q5057052
77. Brd-k86930074-001-01-9
78. 4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-yl-propoxy)-quinazoline
79. Av3
| Molecular Weight | 450.5 g/mol |
|---|---|
| Molecular Formula | C25H27FN4O3 |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 450.20671890 g/mol |
| Monoisotopic Mass | 450.20671890 g/mol |
| Topological Polar Surface Area | 72.5 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 625 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
Cediranib is a once-daily, orally available, highly potent and selective VEGF signalling inhibitor that inhibits all three VEGF receptors. The preclinical profile of Cediranib indicates that it has the potential to be the 'best in class' VEGF signalling inhibitor. Phase I data indicate that Cediranib is generally well tolerated, with the most common dose related adverse events being diarrhoea, hoarseness, headache and hypertension.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EK - Vascular endothelial growth factor receptor (vegfr) tyrosine kinase inhibitors
L01EK02 - Cediranib
Absorption
Available following oral administration.
12 to 35 hours
Cediranib inhibits vacular endothelial growth factor (VEGF) receptor tyrosine kinase (RTK). By forming a blockade at the VEGF receptors, Cediranib limits the growth of new blood vessels, which are essential to supporting tumor growth. Thus, lacking sufficient blood supply, tumor cells become starved for nutrients, slowing or halting growth and potentially improving the efficacy of other treatments. Preclinical evidence indicated that the drug had a high affinity at these sites, and was well tolerated and efficacious in animal studies.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
80
PharmaCompass offers a list of Cediranib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cediranib manufacturer or Cediranib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cediranib manufacturer or Cediranib supplier.
PharmaCompass also assists you with knowing the Cediranib API Price utilized in the formulation of products. Cediranib API Price is not always fixed or binding as the Cediranib Price is obtained through a variety of data sources. The Cediranib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cediranib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cediranib, including repackagers and relabelers. The FDA regulates Cediranib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cediranib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cediranib supplier is an individual or a company that provides Cediranib active pharmaceutical ingredient (API) or Cediranib finished formulations upon request. The Cediranib suppliers may include Cediranib API manufacturers, exporters, distributors and traders.
Cediranib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cediranib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cediranib GMP manufacturer or Cediranib GMP API supplier for your needs.
A Cediranib CoA (Certificate of Analysis) is a formal document that attests to Cediranib's compliance with Cediranib specifications and serves as a tool for batch-level quality control.
Cediranib CoA mostly includes findings from lab analyses of a specific batch. For each Cediranib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cediranib may be tested according to a variety of international standards, such as European Pharmacopoeia (Cediranib EP), Cediranib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cediranib USP).
